Frontiers in oncology

Cancer outcomes and biological effects in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists

Updated

Abstract

This systematic review and meta-analysis evaluated cancer outcomes among adults with type 2 diabetes using glucagon-like peptide-1 receptor agonists (GLP-1RAs).

  • GLP-1RAs may influence cancer outcomes in patients with type 2 diabetes mellitus (T2DM).
  • The analysis assessed both overall cancer incidence and site-specific cancer types.
  • Uncertainty exists regarding the specific biological mechanisms by which GLP-1RAs could affect tumor development.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

No commercial or financial ties reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free